Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
09 Novembre 2023 - 1:00PM
Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative
biotechnology company developing induced pluripotent stem cell
(iPSC)-derived cell therapies in immuno-oncology, today announced
the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief
Executive Officer and member of the Board, effective December 4,
2023. A proven leader with over 20 years of global experience
across the healthcare industry, Dr. Pfeiffenberger most recently
served as Chief Operating Officer at Neogene Therapeutics, a wholly
owned subsidiary of AstraZeneca focused on developing cell
therapies for the treatment of cancer. In connection with the
appointment, Greg Russotti, Ph.D., who has served as Century’s
Interim Chief Executive Officer since April 2023, will assume the
role of Chief Technology and Manufacturing Officer, an expanded
role from his previous position as Chief Technology Officer.
“Brent is a strong leader with extensive
experience across the research, development, and commercialization
of lifesaving drugs. His unique strategic leadership and
operational acumen will serve Century well, and we are thrilled to
have him join as Chief Executive Officer,” said Joe Jimenez,
Chairman of the Board. “On behalf of the entire Board, I would like
to thank Greg Russotti for his exceptional leadership and
unwavering dedication during the interim period. We look forward to
his continued contributions in the newly created role of Chief
Technology and Manufacturing Officer, as Century looks to leverage
its manufacturing expertise and state-of-the-art GMP manufacturing
facility to generate additional value.”
“Century is a pioneer on the cutting-edge of the
allogeneic cell therapy space, and with its first clinical data
readout expected by year-end, it is an honor to join as Chief
Executive Officer at this exciting time,” said Dr. Pfeiffenberger.
“Leveraging the proprietary Allo-Evasion™ platform, the Company is
uniquely positioned to develop differentiated allogeneic cell
therapies and expand patient access to life-saving medicines. I
look forward to working alongside Greg and the talented Century
team to continue to advance the Company’s innovative pipeline and
serve patients in need.”
As Chief Operating Officer of Neogene
Therapeutics, Dr. Pfeiffenberger played a central role in driving
Neogene’s evolution from a preclinical company to a global,
clinical-stage organization with multiple assets, ultimately
culminating in its acquisition by AstraZeneca earlier this year.
Prior to Neogene, Dr. Pfeiffenberger spent nearly two decades in
leadership roles of increasing responsibility at Bristol Myers
Squibb, most recently as Senior Vice President, Head of U.S.
Oncology, where he oversaw business operations for the
multi-billion dollar franchise. Prior to this role, he held several
critical global leadership positions where he built, led, and
expanded commercial and business operations, including as Co-Lead,
Head of Worldwide Commercial Oncology, where he closely partnered
with the Research and Development team on the creation and delivery
of global development strategies for a large-scale oncology
program. He began his career at Bristol Myers Squibb serving in
several roles across a broad range of functions and therapeutic
areas, including marketing, sales, market access and pricing,
business development, and strategy and operations. Dr.
Pfeiffenberger received his Pharm.D. from Duquesne University and
his MBA from the Wharton School of Business at the University of
Pennsylvania.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is
harnessing the power of adult stem cells to develop curative cell
therapy products for cancer that we believe will allow us to
overcome the limitations of first-generation cell therapies. Our
genetically engineered, iPSC-derived iNK and iT cell product
candidates are designed to specifically target hematologic and
solid tumor cancers. We are leveraging our expertise in cellular
reprogramming, genetic engineering, and manufacturing to develop
therapies with the potential to overcome many of the challenges
inherent to cell therapy and provide a significant advantage over
existing cell therapy technologies. We believe our commitment to
developing off-the-shelf cell therapies will expand patient access
and provide an unparalleled opportunity to advance the course of
cancer care. For more information on Century Therapeutics please
visit www.centurytx.com.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking
statements within the meaning of, and made pursuant to the safe
harbor provisions of, The Private Securities Litigation Reform Act
of 1995. All statements contained in this press release, other than
statements of historical facts or statements that relate to present
facts or current conditions, including but not limited to,
statements regarding our clinical development plans and timelines,
are forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance, or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this press release are only predictions. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control, including, among others: our ability to
successfully advance our current and future product candidates
through development activities, preclinical studies, and clinical
trials; our dependence on the success of our lead product
candidate, CNTY-101,our ability to obtain FDA acceptance for our
future IND submissions and commence clinical trials on expected
timelines, or at all; our reliance on the maintenance of certain
key collaborative relationships for the manufacturing and
development of our product candidates; the timing, scope and
likelihood of regulatory filings and approvals, including final
regulatory approval of our product candidates; the impact of the
effects of the COVID-19 pandemic, geopolitical issues, banking
instability and inflation on our business and operations, supply
chain and labor force; the performance of third parties in
connection with the development of our product candidates,
including third parties conducting our clinical trials as well as
third-party suppliers and manufacturers; our ability to
successfully commercialize our product candidates and develop sales
and marketing capabilities, if our product candidates are approved;
our ability to recruit and maintain key members of management and
our ability to maintain and successfully enforce adequate
intellectual property protection. These and other risks and
uncertainties are described more fully in the “Risk Factors”
section of our most recent filings with the Securities and Exchange
Commission and available at www.sec.gov. You should not rely on
these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking
statements may not be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. Moreover, we operate in a dynamic industry and economy.
New risk factors and uncertainties may emerge from time to time,
and it is not possible for management to predict all risk factors
and uncertainties that we may face. Except as required by
applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
For More Information:
Investors and Media: Argot Partners –
century@argotpartners.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/9752d1d6-78f7-4d63-a7e6-03623adae000
Grafico Azioni Century Therapeutics (NASDAQ:IPSC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Century Therapeutics (NASDAQ:IPSC)
Storico
Da Set 2023 a Set 2024